Tel Aviv Sourasky MC
Welcome,         Profile    Billing    Logout  
 9 Trials 
11 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Karni, Arnon
NCT03362294: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

Active, not recruiting
2
30
RoW
GA Depot 40mg once monthly, GA Depot 25mg once monthly
Mapi Pharma Ltd.
Primary Progressive Multiple Sclerosis
08/26
09/26
NCT03696485: Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS

Withdrawn
1/2
12
RoW
SCM-010
Stem Cell Medicine Ltd.
Secondary Progressive Multiple Sclerosis (SPMS)
02/25
02/25
Fishman, Sigal
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Samuelov, Liat
NCT06073132: An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Recruiting
2/3
80
Europe, US, RoW
AC-203, Vehicle
TWi Biotechnology, Inc.
Generalized Epidermolysis Bullosa Simplex
08/25
03/26
NCT04908215 / 2021-000214-42: INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa

Completed
2
19
Europe, RoW
INM-755 (cannabinol) cream, Vehicle Cream
InMed Pharmaceuticals Inc.
Epidermolysis Bullosa Simplex, Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica, Kindler Syndrome
04/23
04/23
NCT04307862: Safety, Tolerability and Efficacy of ZEP-3Na (0.1% or 1%) Compared to Placebo in Subjects With Mild to Moderate Atopic Dermatitis

Recruiting
2
165
RoW
ZEP-3Na 0.1%, ZEP-3Na 1%, Placebo Vehicle only
Shulov Innovate for Science Ltd. 2012
Atopic Dermatitis
12/24
02/25
Komarov, Irina
NCT03362294: Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

Active, not recruiting
2
30
RoW
GA Depot 40mg once monthly, GA Depot 25mg once monthly
Mapi Pharma Ltd.
Primary Progressive Multiple Sclerosis
08/26
09/26
Konigstein, Maayan
IonMAN, NCT05364697: Trial- First in Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System

Active, not recruiting
N/A
60
RoW
IoNIR Ridaforolimus-Eluting Coronary Stent System, IoNIR
Medinol Ltd.
Coronary Stenosis, Coronary Disease, Non-ST Elevated Myocardial Infarction, Cardiovascular Diseases
09/24
12/29
SATURATION, NCT06393478: Southeastern Europe Microcirculation Registry

Recruiting
N/A
900
Europe, RoW
Institute for Cardiovascular Diseases "Dedinje", Abbott Medical Devices
Angina, Microvascular, Coronary Microvascular Dysfunction, Coronary Artery Disease
03/29
03/34
NCT05909748: FIH Study of the GEMINUS TAVI System in Patients With Severe Symptomatic Aortic Stenosis

Recruiting
N/A
30
RoW
GEMINUS Transcatheter Aortic Valve Implantation system, GEMINUS TAVI system
Valve Medical
Aortic Valve Stenosis
05/25
04/30

Download Options